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Blood components transfused to hematopoietic stem cell transplant (HSCT) recipients are irradiated to
prevent transfusion-associated graft-versus-host disease (TA-GVHD). The effect of transfusing non-irradiated
blood products in HSCT outcome, including incidence of transplant complications, bacterial infections, acute
and chronic GVHD presentation, and characteristics, has not been documented. Clinical records as well as
blood bank and electronic databases of HSCT patients grafted after reduced-intensity conditioning who
received irradiated versus non-irradiated blood products, after blood irradiation became unavailable at our
center, were scrutinized for transplant outcome, clinical evolution, engraftment characteristics including days
to neutrophil and platelet recovery, acute and chronic GVHD, rate and type of infections, and additional
transplant-related comorbidities. All transfused blood products were leukoreduced. A total of 156 HSCT re-
cipients was studied, 73 received irradiated and 83 non-irradiated blood components. Bacterial infections
were signiﬁcantly more frequent in patients transfused with non-irradiated blood products, P ¼ .04. Clinically
relevant increased rates of fever and neutropenia and mucositis were also documented in these patients. No
cases of TA-GVHD occurred. Classical GVHD developed in 37 patients (50.7%) who received irradiated blood
products and 36 (43.9%) who received non-irradiated blood products, P ¼ .42. Acute GVHD developed in 28
patients (38.4%) in the blood-irradiated and 33 patients (39.8%) in the non-irradiation group, P ¼ .87. The 2-
year GVHD-free survival rate was 40% in the irradiated versus 40.6% in the non-irradiation group, P ¼ .071.
Increased bacterial infections were found in HSCT recipients transfused with non-irradiated blood products,
which ideally must always be irradiated.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
A considerable body of clinical, basic science and animal
model data have demonstrated that blood transfusions have
signiﬁcant effects on the immune system, including dysre-
gulation of inﬂammation and innate immunity leading to
susceptibility to microbial infection and down-regulation of
cellular (T and natural killer cells) host defenses against tu-
mors [1]. More recently, severe effects attributable to allo-
geneic blood transfusion by pro-inﬂammatory mechanisms,edgments on page 529.
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ty for Blood and Marrow Transplantation.including multiple-organ failure and increased mortality,
have been related to the transfusion-related immunomodu-
lation (TRIM) effect [2]. Different mechanisms have been
implicated in TRIM pathogenesis, including the presence of
allogeneic mononuclear cells, WBC-derived soluble media-
tors, and soluble HLA peptides circulating in allogeneic
plasma [3].
Although the immunomodulatory effects of allogeneic
blood transfusion are not completely identiﬁed, there is
sufﬁcient evidence that both humoral and cellular immunity
are altered [4]. In this respect, we previously showed that
blood transfusion is associated to decreased overall survival
in children with acute lymphoblastic leukemia, probably
through the TRIM effect [5].
Transfusion-associated graft-versus-host disease (TA-
GVHD) is a rare catastrophic complication seen in hemato-
poietic transplant recipients, resulting from the patient’s
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context of variable HLA similarity. Other susceptible patients
include thosewho are immunosuppressed, including fetuses,
very premature neonates, and patients who have an
increased likelihood of possessing 1 HLA haplotype for which
the blood component donor is homozygous [6]. Transfusion
of irradiated blood components to prevent TA-GVHD is a
time-honored standard of care in the support of bone
marrow and hematoprogenitor transplant recipients [7].
Irradiation eliminates the proliferative capacity of T cells
present in blood products [8]. T cell proliferation is halted by
a 2500-cGy radiation dose, a standard recommended by the
US Food and Drug Administration for all blood products [9].
Classical GVHD, on the other hand, is commonly observed
after allogeneic hematopoietic stem cell transplant (allo-
HSCT) but rarely after transfusion or solid organ trans-
plantation [10]. GVHD is a major cause of morbidity and
mortality, affecting 40% to 60% of recipients of an allo-HSCT,
accounting for 15% of deaths after this intervention [11]. TA-
GVHD differs from the classical form by its earlier presen-
tation and involvement of the bone marrow, commonly
leading to pancytopenia.
HSCT at our center has been performed for the past 20
years. Since the year 2000 we almost exclusively carry out
hematopoietic grafting, using a reduced-intensity condi-
tioning (RIC) regimen in an ambulatory setting developed at
our and other centers [12,13]. RIC regimens cause less dam-
age and less allo-GVHD [14] than total irradiation regimens.
Because of budget restrictions at our public institution, no
blood irradiator is available, leading us to make the decision
to halt irradiation of blood products intended for HSCT pa-
tients after 2010. Before this year a linear accelerator at the
oncology department, no longer available, was used for
blood irradiation.
No studies documenting the effects of transfusing non-
irradiated leukoreduced blood components to recipients of
an allogeneic HSCT have been published. Mononuclear cells
in non-irradiated blood products can modulate the immune
status of the recipient through several mechanisms [3], with
the potential to alter the dynamics of transplant recovery.
We investigated differences in relevant aspects of transplant
outcome, including days to neutrophil and platelet engraft-
ment, infections, mucositis, and other complications as well
as possible cases of TA-GVHD and rates of acute and chronic
GVHD, between patients receiving irradiated versus non-
irradiated leukoreduced blood components.METHODS
A retrospective study was performed at the Hematology Department,
Internal Medicine Division of the “Dr. José Eleuterio Gonzalez” University
Hospital of the School of Medicine of the Autonomous University of Nuevo
Leon, in Monterrey, México. The Ethics and Human Research Committees at
the institution approved the study protocol.
We reviewed the clinical records of 156 hematology patients trans-
planted at our center who subsequently received transfusion of leukore-
duced blood components from 2008 through 2013. Transfusion of products
obtained from blood donated by relatives was avoided. Mobilized peripheral
blood stem cells from HLA-identical sibling donors were used in all cases.
For the purposes of the study, patients were divided in group 1 (n¼ 73), who
received irradiated leukoreduced blood components, and group 2 (n ¼ 83),
those transfused with non-irradiated leukoreduced blood products
after 2010.
Information regarding the source of the hematopoietic stem cells and
time to recovery of the absolute neutrophil count  .5  109/L and to a
platelet count  20  109/L was obtained from the clinical records and
electronic databases. The number, type, and frequency of blood products
prepared and administered according to standard procedures were docu-
mented directly from the clinical ﬁles and the blood bank database.Leukoreduction was carried out by microﬁltration at the bedside using
Sepacell PLS-10A ﬁlters (Fenwall Inc., Lake Zurich, IL) following the in-
structions provided by the manufacturer. This leukoreduction method was
used along the study for both groups. Standard bacterial cultures and
serological tests were done for identifying etiological agents in all patients
with suspected infection.
A RIC regimen, which causes less damage and less allo-GVHD [14] than
total irradiation regimens, has been administered in an ambulatory basis at
our center since the year 2000 [12]. Brieﬂy, it consists of a scheme with
dosage based on ideal weight, which includes busulfan 4 mg/kg p.o on
days 6 and 5; cyclophosphamide 350 mg/m2 once daily i.v. on
days 4, 3, and 2; ﬂudarabine 30 mg/m2 i.v. once daily on days 4, 3,
and 2; cyclosporine A (CyA) 5 mg/kg p.o. starting on day 1; and meth-
otrexate 5 mg/m2 i.v. on daysþ1, þ3, þ5, and þ11. CyA is continued through
to day 180, with adjustments to obtain serum CyA levels of 150 to 275 ng/
mL, and then tapered over 30 to 60 days [12]. In patients with aplastic
anemia, busulfan was not used and the cyclophosphamide dose was
doubled from days 4 to 1. If GVHD developed, CyA was tapered over
longer periods. Ondansetron 1 mg i.v. every hour over 4 hours after
chemotherapy, an oral quinolone, and an azole were used in all patients
until granulocytes were >.5  109/L.
Donor lymphocyte infusions in allograft recipients were used if there
was no evidence of GVHD 100 days after the transplant and if there was
evidence of persisting or relapsedmalignancy. Donors were stimulated with
10 mg/kg of granulocyte colony-stimulating factor s.c. for 5 days before
CD34þ cell automated collection [13]. CD34þ cells at a dose 2.5106/kg of
body weight were infused on day 0. Afterward, patients were closely fol-
lowed at the hematology transplant clinic to document time to neutrophil
and platelet recovery to 500/mL and 20,000/mL, respectively.
Engraftment was also assessed by chimerism analysis by ﬂow cytom-
etry, and clinical follow-up was carried out on an outpatient basis. Trans-
plants are performed as an outpatient procedure to make this modality of
therapy ﬁnancially viable and to reduce the risk of hospital-acquired post-
transplant infections [12,13]. Diagnosis of acute and chronic GVHD was
established based on previous guidelines [15,16].Statistical Analysis
For data analysis, SPSS v.20.0 for MAC was used (IBM Corp., Armonk,
NY). Descriptive analysis was performed, obtaining means and standard
deviations or medians and ranges according to the variables distribution
calculated with Kolmogorov-Smirnov. Fisher’s test was used for 2 2 tables.
Event-free survival was determined with the Kaplan-Meier method, calcu-
lating time, status, cumulative survival, and standard error with a 95%
conﬁdence interval (CI). Equality of data distributionwas estimated with the
log-rank test. A 2-sided P ¼ .05 was considered statistically signiﬁcant.RESULTS
The general characteristics of the 156 patients as well as
the type of blood product transfused, irradiated and non-
irradiated, and number of blood products transfused are
shown in Table 1. A secondary analysis regarding proportion
of blood products transfused between groups was carried
out, ﬁnding no statistical difference for either packed RBCs
(.294) or platelet concentrates and single-donor platelet
pheresis (.072) (Table 1).
Table 2 displays neutrophil and platelet recovery time
(days). No case of TA-GVHD developed in the period of study
in either group. Regarding differences in classical GVHD, it
was found that 37 patients (50.7%) received irradiated blood
components and 36 (43.9%) non-irradiated blood products,
P ¼ .42 (odds ratio [OR], 1.31; 95% CI, .68 to 2.47). Twenty-
eight patients (38.4%) developed acute GVHD in the irradi-
ated versus 33 (39.8%) in the non-irradiated blood
components group, P ¼ .87 (OR, .94; 95% CI, .49 to 1.79). Ten
patients (13.7%) progressed from acute to chronic GVHD in
the blood irradiation and 14 (16.9%) in the non-irradiation
group, P ¼ .66 (OR, .78; 95% CI, .32 to 1.88). Complete data
are shown in Table 3.
Differences inmorbidities between groupswere assessed,
and although no statistical differences were found, a higher
clinical incidence in comorbidities was documented in the
group of HSCT patients transfused with non-irradiated blood
Table 3
GVHD Incidence According to Type of Leukoreduced Blood Product
Transfused
Parameters Irradiated
Blood
Products
(n ¼ 73)
Non-Irradiated
Products
(n ¼ 83)
P OR 95% CI
GVHD 37 (50.7) 36 (43.9) .42 1.31 .68-2.47
Acute GVHD 28 (38.4) 33 (39.8) .87 .94 .49-1.79
Acute to chronic
GVHD
10 (13.7) 14 (16.9) .66 .78 .32-1.88
De novo chronic
GVHD
9 (12.3) 3 (3.6) .68 3.75 .97-14.42
Values in parentheses are percents.
Table 1
General Characteristics of 156 Patients Receiving HSCT and Number of Blood
Products Transfused after RIC Transfused with Irradiated vs. Non-Irradiated
Leukoreduced Blood Components
Parameters Irradiated Blood
Products (n ¼ 73)
Non-Irradiated
Products (n ¼ 83)
P
Median age, yr (range) 21 (1-67) 26 (1-61) .698
Gender .327
Male 47 (64.4) 46 (55.4)
Female 26 (35.6) 37 (44.6)
Diagnosis .002
Leukemia 31 (42.5) 62 (73.5)
Myeloma 5 (6.8) 1 (1.2)
Myelodysplastic
syndrome
18 (24.7) 12 (14.5)
Lymphoma 10 (13.7) 6 (7.2)
Other* 9 (12.3) 3 (3.6)
Blood products transfused (range)
Packed RBCs 2 (1-25) 2 (1-64) .546
Platelet concentrate 2 (1-32) 3 (1-40) .033
Platelet apheresis 1 (0-34) 1 (0-19) .568
Patients transfused with
RBCs 55 (75.3) 56 (67.5) .294
Platelet products .072
Platelet concentrate 15 (24.6) 27 (37)
Platelet pheresis 5 (8.2) 1 (1.4)
Both 41 (67.2) 45 (61.6)
Values are total number of cases with percents in parentheses unless
otherwise indicated.
* Other includes thalassemia, paroxysmal nocturnal hemoglobinuria,
sickle cell anemia, and Wiskott-Aldrich syndrome.
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infections was documented, ﬁnding 1 bacterial infection in
the irradiated group (11.1%) versus 10 in the non-irradiation
group (52.6%), P ¼ .04 (OR, .11; 95% CI, .01 to 1.80) (Table 4).
Speciﬁc bacteria and other microorganisms involved are
displayed in Table 5. At the 2-year post-transplantation
follow-up, GVHD-free survival was 40% (95% CI, 26% to
53%) in the irradiated group versus 40.6% (95% CI, 25% to 55%)
in the non-irradiation group, P ¼ .071 (Figure 1).Table 4
Incidence of Morbidities According to Type of Leukoreduced Blood Product
Received, Irradiated vs. Non-Irradiated, after HSCT in 156 Recipients
Parameters Irradiated Blood
Products
Non-Irradiated
Products
P OR 95% CIDISCUSSION
The aim of this study was to investigate if there were
differences in signiﬁcant clinical outcomes after transfusion
of irradiated versus non-irradiated leukoreduced blood
products in recipients of allo-HSCT after RIC. Compared with
myeloablative regimens, RIC schemes produce less GVHD
[14] and are associated with a decreased release of pro-
inﬂammatory cytokines because of limited tissue damage
during administration [17,18] and a transient and potentially
tolerogenic state of mixed donorehost chimerism [19,20].
These differences may account for the lower rates of severe
GVHD after unrelated HSCT with RIC [14,21]. Here, we found
that acute and chronic GVHD developed equally and with the
same severity between HSCT recipients transfused withTable 2
Neutrophil and Platelets Recovery Time (Days) after RIC Regimen Performed
as an Outpatient Procedure for 156 Patients According to the Type of Leu-
koreduced Blood Product Transfused
Parameters Irradiated Blood
Products (n ¼ 73)
Non-Irradiated
Products (n ¼ 83)
P
Recovery, days
Neutrophil 16 (8-55) 15 (8-25) .33
Platelet transfusions 14 (6-70) 14 (8-39) .597
Values in parentheses are ranges.irradiated or non-irradiated leukoreduced blood compo-
nents, indicating that blood transfusion per se does not in-
ﬂuence GVHD development or clinical course in these
patients. The less aggressive RIC regimen used could leave
our transplant recipients with a higher capacity to limit an
alloimmune T cell attack, thus reducing the risk of devel-
oping TA-GVHD.
Allogeneic blood transfusion itself is a major immuno-
logical challenge. The immunomodulatory effect of trans-
fusion has long been recognized and associated to beneﬁcial
as well as adverse outcomes, like increased cancer recur-
rence and susceptibility to infectious postsurgical compli-
cations [3,22,23]. Transfusion can result in a
pro-inﬂammatory allo-response, eliciting both antibody
and cellular responses against donor-speciﬁc antigens [24-
29]. Thus, the immune burden of transfusion could
contribute to additional engraftment challenges in HSCT re-
cipients, and this effect could be more pronounced in pa-
tients transfused with non-irradiated leukoreduced blood
products, containing biologically active lymphocytes, able to
exert an immunomodulatory or immunosuppressive effect
that can contribute to the increase in comorbidities observed
in our study, particularly bacterial infections.
No case of TA-GVHD developed during the period of study
in 83 consecutive HSCT recipients transfused with leukore-
duced non-irradiated blood products. Current standards
deﬁne a leukoreduced component as one with <5  106 re-
sidual leukocytes. Available leukoreduction ﬁlters and
apheresis systems are capable of consistently producing
components with <1  106 residual leucocytes, meeting
either American or European cutoff standards [30]. Trans-
fusion of non-irradiated leukoreduced blood products to(n ¼ 73) (n ¼ 83)
Fever and
neutropenia
26 (35.6) 40 (48.2) .14 .59 .31-1.13
Infections* 9 (12.3) 19 (22.9) .08 .47 .19-1.12
Viral 4 (44.4) 6 (31.6)
Bacterial 1 (11.1) 10 (52.6)
Fungal 4 (44.4) 3 (15.8)
Secondary analysis bacterial vs. nonbacterial .04 .11 .01-1.08
Bacterial 1 (11.1) 10 (52.6)
Nonbacterial 8 (88.9) 9 (47.4)
Mucositis 18 (24.7) 25 (30.1) .47 .75 .37-1.54
Values in parentheses are percents.
* Infections were included in the fever and neutropenia group.
Table 5
Bacteria and Other Microorganisms Involved in Infectious Episodes in HSCT
Recipients Transfused with Leukoreduced Irradiated vs. Non-Irradiated
Blood Products
Parameters Irradiated Blood
Products (n ¼ 73)
Non-Irradiated
Products (n ¼ 83)
P
Agent .08
E. coli þ C. difﬁcile 1 0
Pseudomonas 0 2
Toxoplasma 0 1
Klebsiella 0 2
Staphylococcus 0 3
Acinetobacter 0 2
CMV 4 3
BK virus 0 1
Herpes labial 0 2
Candida 4 1
Aspergillus 0 2
CMV indicates cytomegalovirus.
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number of T cells below the threshold needed to prompt the
immune sequence needed for this complication to develop.
Another intriguing possibility for the lack of TA-GVHD in this
study is that the degree of HLA diversity in the Mexican
population lowers the probability of shared HLA antigens
among recipients and donors, resulting in a decreased
chance of developing the biological sequence needed for TA-
GVHD to occur. In populations with lower diversity of HLA,
and thus increased probability of sharing HLA antigens, such
as the Japanese, there is a greater probability of developing
TA- GVHD resulting from a higher chance of HLA semi-
identity between recipient and donor [31]. In addition, RIC
regimens could leave the recipient with a higher capacity to
limit an alloimmune T cell attack, thus reducing the risk of
developing TA-GVHD compared with myeloablative
schemes. Further studies adequately powered and includingFigure 1. The 2-year GVHD event-free survival was 40% (95% CI, 26% to 53%) in
the group of 73 HSCT recipients transfused with irradiated blood products,
compared with 40.6% (95% CI, 25% to 55%) in the group of 83 patients receiving
non-irradiated blood components, P ¼ .071.representative groups of speciﬁc hematologic pathologies
are required to test this hypothesis.
A statistically signiﬁcant higher incidence of bacterial
infections in the group transfused with non-irradiated blood
products was documented. In this respect, allogeneic blood
transfusion exposes the recipient to large amounts of allo-
antigens in soluble and cell-associated forms and can create
conditions for the TRIM effect to develop [3,32]. Different
mechanisms have been implicated in TRIM pathogenesis,
including the presence of allogeneic mononuclear cells,
WBC-derived soluble mediators, and soluble HLA peptides
circulating in allogeneic plasma [32]. The mechanisms that
mediate the TRIM effect might be heightened in our HSCT
recipients of non-irradiated blood products through the ac-
tions and products of biologically active mononuclear cells
with immunomodulatory properties, rendering them more
susceptible to morbidities.
In addition to TRIM, TA microchimerism occurs inde-
pendently of leukoreduction [33], with similar rates of TA
microchimerism demonstrated after transfusion with both
leukoreduced and non-leukoreduced products. The clinical
signiﬁcance of enduring chimerism could include both
adverse effects such as autoimmune diseases [34] and
potential therapeutic beneﬁts, including tolerance induc-
tion and tissue regeneration and repair [35,36]. Potentially,
TA microchimerism could result in immunomodulatory
effects in HSCT recipients that might favor additional
immunosuppression and comorbidities, although this has
not been studied and remains to be deﬁned. Alternatively,
bacterial infections observed could be related to changes in
resistance patterns with respect to quinolone prophylaxis
that might also be in play, and this could be either a time
period cohort effect or a difference arising by chance in the
context of relatively small numbers of patients.
It is important to underscore the limitations in our study,
because of its retrospective design and the relatively small
sample size. However, a uniform ambulatory RIC transplant
regimen was used for all diagnostic categories as well as
standardized transfusion practices, and robust statistical
analysis of all critical variables led to clear-cut results.
There were a statistically signiﬁcant higher number of
bacterial infections as well as a clinically relevant increase in
comorbidities, including fever, neutropenia, and mucositis in
HSCT recipients transfused with non-irradiated leukore-
duced blood products. Urgent situations where HSCT re-
cipients should be transfused with non-irradiated blood
products can develop; thus, it is important for treating
physicians to be aware that this can confer an increased risk
of serious infection and monitoring of this eventuality is
mandatory.
No clear differences in major transplant outcomes of TA-
GVHD, conventional GVHD, viral infections, or survival
were documented, leading to the conclusion that with
modern leukoreduction techniques in use, irradiation of
blood products may not be as important as it once was. To
conﬁrm this hypothesis, further studies are needed.ACKNOWLEDGMENTS
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